Overview

Nintedanib addresses the redundancy that lets tumors evade single-pathway anti-angiogenic therapy by simultaneously occupying VEGFR, FGFR, and PDGFR kinase domains. This multi-pronged blockade delays the vascular remodeling that underpins acquired resistance after first-line bevacizumab or VEGF-directed treatment. Supplied as 100 mg soft capsules, two are taken twice daily to reach the 200 mg target, so resistance management depends as much on adherence as on the molecule's breadth. Its dual role in adenocarcinoma and fibrosis reflects the same fibroblast-targeting mechanism.

How It Works

Tumors recruit new vessels through several parallel growth-factor loops, so blocking only VEGF leaves FGFR and PDGFR pathways free to compensate. Nintedanib binds the intracellular kinase domains of VEGFR1–3, FGFR1–3, and PDGFRα/β, dampening signal transduction across all three axes at once. In idiopathic pulmonary fibrosis the same inhibition calms proliferating fibroblasts, which explains its second indication. By hitting multiple receptors, it raises the barrier that endothelial cells must overcome to rebuild blood supply, buying time before resistant vasculature re-forms.

Indications

Nintedanib is used as second-line or later therapy for advanced non-small cell lung cancer of adenocarcinoma histology, and as a treatment for idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease. In NSCLC it is combined with docetaxel after first-line chemotherapy. Candidate selection rests on histology and prior therapy rather than a single biomarker, with resistance history guiding sequencing. Therapy continues until progression or unacceptable side effects such as diarrhea or hepatotoxicity.

Dosage & Administration

The labeled dose is 200 mg daily, given as two 100 mg soft capsules taken approximately 12 hours apart with food. Capsules must be swallowed whole; the soft-gel formulation is sensitive to handling. Dose holds or reductions follow the prescribing rules when liver enzymes or gastrointestinal toxicity rise. Because effect depends on sustained receptor coverage, missing doses weakens the anti-resistance pressure the regimen is designed to maintain.

Storage & Sourcing

Store 100 mg capsules at 2–8 °C or up to 25 °C in the original blister, away from moisture and light; do not freeze. The pack should arrive under a documented ambient or refrigerated chain depending on the supplier's validation. Verify batch and expiry on receipt, rotate stock by earliest expiry, and quarantine any blistered pack that shows softening or leakage outside labeled limits.

FAQ

Q: How does nintedanib reduce resistance compared with single-target VEGF inhibitors?

A: VEGF-only blockers leave FGFR and PDGFR loops active, letting vessels regrow through alternate signals. Nintedanib hits all three receptor families, so the tumor must rebuild angiogenesis across several blocked pathways at once.

Q: When is nintedanib used after first-line therapy fails?

A: In adenocarcinoma NSCLC it follows platinum-based chemotherapy, often with docetaxel, to counter the angiogenic rebound that single-agent VEGF therapy could no longer control.

Q: Can nintedanib be combined with chemotherapy despite resistance concerns?

A: Yes; in NSCLC it is paired with docetaxel, where its multi-kinase blockade complements cytotoxic effect while the chemotherapy addresses proliferating clones the anti-angiogenic arm misses.

Q: What biomarkers predict nintedanib benefit in adenocarcinoma?

A: No single mutation is required; histology (adenocarcinoma) and prior treatment pattern drive selection, with resistance to earlier VEGF-directed therapy supporting its sequencing.